Prof. Mingyan E 鄂明艳
Chief Physician, Professor
Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiotherapy and comprehensive treatment for malignant tumors, with a focus on standardized and individualized care for lung, esophageal, mediastinal, and breast cancers.
Dr. E is a Chief Physician and Professor with nearly 30 years of experience in tumor radiotherapy, teaching, and research. Basic research focuses on gene therapy and cardiac radiation protection. Dr. E has published multiple papers in core journals and SCI-indexed publications, received provincial science and technology awards, and leads multi-center clinical trials on radiotherapy combined with targeted drugs.
Professional roles
- Member, Radiation Oncology Branch, Chinese Medical Association
- Member, Esophageal Cancer Group, Radiation Oncology Branch, Chinese Medical Association
- Vice Chair, Radiotherapy Professional Committee, Heilongjiang Anti-Cancer Association
- Vice Chair, Geriatric Oncology Professional Committee, Heilongjiang Province
Name order: in Chinese the family name comes first (E Mingyan). Papers usually list the name as Mingyan E or E M.
Selected publications
24 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Br J Pharmacol, 2026 (senior author): Mitochondrial DNA-cGAS-STING induces macrophage pyroptosis via phospho-IRF3-mediated NLRP3 expression in ionising radiation-induced atherosclerosis progression. PubMed 43023830
- J Am Heart Assoc, 2025 (senior author): Single-Cell RNA Sequencing Reveals Granzyme K(+) CD8(+) T Cells as a Target for Mitigating Plaque Instability Following Radiation. PubMed 40913272
- Nanoscale Adv, 2025 (senior author): Ultrasound-activated nano-oxygen sensitizer for sonodynamic-radiotherapy of esophageal cancer. PubMed 40007570
- Zhongguo Fei Ai Za Zhi, 2023 (senior author): [Research Progress on the Protective Effect of Intestinal Flora on Radiation-induced Lung Injury in Thoracic Tumors]. PubMed 37488084
- Front Pharmacol, 2023 (senior author): Molecular characterization based on tumor microenvironment-related signatures for guiding immunotherapy and therapeutic resistance in lung adenocarcinoma. PubMed 36726580
- Expert Rev Clin Pharmacol, 2020 (senior author): Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma. PubMed 33115264
- Zhongguo Fei Ai Za Zhi, 2020 (senior author): [Mechanism and Research Progress of Microbiome in the Development of Lung Cancer]. PubMed 32819055
- BMC Pharmacol Toxicol, 2019 (senior author): Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours. PubMed 31661009
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion